Wikipedia

Hepatitis E

(Redirected from Hepatitis E vaccine)

Hepatitis E is inflammation of the liver caused by infection with the hepatitis E virus (HEV);[4][5] it is a type of viral hepatitis.[6] Hepatitis E has mainly a fecal-oral transmission route that is similar to hepatitis A, although the viruses are unrelated.[7][8][9] HEV is a positive-sense, single-stranded, nonenveloped, RNA icosahedral virus and one of five known human hepatitis viruses: A, B, C, D, and E.

Hepatitis E
Hepatitis E virus
SpecialtyInfectious disease, Hepatology
SymptomsNausea, jaundice[1]
ComplicationsLiver failure[1]
CausesHepatitis E virus (HEV)[1]
Diagnostic methodBlood test[1]
Differential diagnosisHepatitis A[2]
TreatmentRest, ribavirin (if chronic)[1]
Frequency28 million worldwide (2013)[3]

Like hepatitis A, hepatitis E usually follows an acute and self-limiting course of illness (the condition is temporary and the individual recovers) with low death rates in resource-rich areas; however, it can be more severe in pregnant women and people with a weakened immune system, with substantially higher death rates. In pregnant women, especially in the third trimester, the disease is more often severe and is associated with a clinical syndrome called fulminant liver failure, with death rates around 20%.[8][10][11] Whereas pregnant women may have a rapid and severe course, organ transplant recipients who receive medications to weaken the immune system and prevent organ rejection can develop a slower and more persistent form called chronic hepatitis E,[12] which is so diagnosed after 3 months of continuous viremia.[13] HEV can be clustered genetically into 8 genotypes, and genotypes 3 and 4 tend to be the ones that cause chronic hepatitis in the immunosuppressed.[14][15][16]

In 2017, hepatitis E was estimated to affect more than 19 million people.[3] Those most commonly at risk of HEV are men aged 15 to 35 years of age.[17] A preventive vaccine (HEV 239) is approved for use in China.[18]

The virus was discovered in 1983 by researchers investigating an outbreak of unexplained hepatitis among Soviet soldiers serving in Afghanistan.[17] The earliest well-documented epidemic of hepatitis E occurred in 1955 in New Delhi and affected tens of thousands of people (hepatitis E virus was identified as the etiological agent at fault retrospectively through testing of stored samples).[19]

Signs and symptoms

edit

Acute infection

edit

The average incubation period of hepatitis E is 40 days, ranging from 2 to 8 weeks. After a short prodromal phase symptoms may include jaundice, fatigue, and nausea, though most HEV infections are asymptomatic. The symptomatic phase coincides with elevated hepatic aminotransferase levels.[20][21][22][23] Viral RNA becomes detectable in stool and blood serum during the incubation period. Serum IgM and IgG antibodies against HEV appear just before the onset of clinical symptoms. Recovery leads to virus clearance from the blood, while the virus may persist in stool for much longer. Recovery is also marked by disappearance of IgM antibodies and increase of levels of IgG antibodies.[8][22]

Chronic infection

edit

While usually lasting weeks and then resolving, in people with weakened immune systems—particularly in people who have had solid organ transplant—hepatitis E may cause a chronic infection.[24] Occasionally this may result in a life-threatening illness such as fulminant liver failure or liver cirrhosis.[25][26]

Other organs

edit

Infection with hepatitis E virus can also lead to problems in other organs. For some of these reported conditions such as musculoskeletal or immune-mediated manifestations the relationship is not entirely clear, but for several neurological and blood conditions the relationship appears more consistent:[27][28][29][30]

Infection in pregnancy

edit

Pregnant women show a more severe course of infection than other populations. Liver failure with mortality rates of 20% to 25% has been reported from outbreaks of genotype 1 and 2 HEV in developing countries. Besides signs of an acute infections, adverse effects on the mother and fetus may include preterm delivery, abortion, stillbirth, and neonatal death.[10][31][32]

The pathological and biological mechanisms behind the adverse outcomes of pregnancy infections remain largely unclear. Increased viral replication and influence of hormonal changes on the immune system are currently thought to contribute to worsening the course of infection.[33] Furthermore, studies showing evidence for viral replication in the placenta or reporting the full viral life cycle in placental-derived cells in vitro suggest that the human placenta may be a site of viral replication outside the liver.[34] The primary reason for HEV severity in pregnancy remains enigmatic.[17]

Virology

edit
Main article: Orthohepevirus A

Classification

edit

HEV is classified into the family Hepeviridae, which is divided in two genera, Orthohepevirus (all mammalian and avian HEV isolates) and Piscihepevirus (cutthroat trout HEV).[33] Only one serotype of the human virus is known, and classification is based on the nucleotide sequences of the genome.[35] Genotype 1 can be further subclassified into five subtypes,[36] genotype 2 into two subtypes,[37] and genotypes 3 and 4 have been divided into 10[38] and seven subtypes.[38] Additionally there are genotypes 5, 6, 7 and 8.[16] Rat HEV was first isolated from Norway rats in Germany,[39] and a 2018 CDC article indicated the detection of rat HEV RNA in a transplant recipient.[40]

Distribution

edit

Genotypes 1 and 2 are restricted to humans and often associated with large outbreaks and epidemics in developing countries with poor sanitation conditions.[41] Genotypes 3 and 4 infect humans, pigs, and other animal species and have been responsible for sporadic cases of hepatitis E in both developing and industrialized countries.[45][46]

Transmission

edit
 
Hepatitis E virus in pork liver sausage (the arrows in panel A point to the virion, those in B, C & D point to bound gold nanoparticles used in virus detection)[47]

Hepatitis E (genotype 1 and, to a lesser extent genotype 2) is endemic and can cause outbreaks in Southeast Asia, northern and central Africa, India, and Central America.[5][48] It is spread mainly by the fecal–oral route due to contamination of water supplies or food; direct person-to-person transmission is uncommon.[5][21] In contrast to genotypes 1 and 2, genotypes 3 and 4 cause sporadic cases thought to be contracted zoonotically, from direct contact with animals or indirectly from contaminated water or undercooked meat.[5][49]

Outbreaks of epidemic hepatitis E most commonly occur after heavy rainfalls, especially monsoons because of their disruption of water supplies; heavy flooding can causes sewage to contaminate water supplies.[50][51]: 78  The World Health Organization recommendation for chlorine on HEV inactivation, a free chlorine residual of 0.5 mg/L (6.7×10−5 oz/US gal) for 30 min (pH, <8.0)[52] Major outbreaks have occurred in New Delhi, India (30,000 cases in 1955–1956),[53] Burma (20,000 cases in 1976–1977),[54] Kashmir, India (52,000 cases in 1978),[55] Kanpur, India (79,000 cases in 1991),[53] and China (100,000 cases between 1986 and 1988).[56] According to Rein et al., HEV genotypes 1 and 2 caused some 20.1 million hepatitis E infections, along with 3.4 million cases of symptomatic disease, and 70,000 deaths in 2005; however the aforementioned paper did not estimate the burden of genotypes 3 and 4.[57]

According to the Department for Environment, Food and Rural Affairs, evidence indicated the increase in hepatitis E in the U.K. was due to food-borne zoonoses, citing a study that found in the U.K. that 10% of pork sausages contained the hepatitis E virus. Some research suggests that food must reach a temperature of 70 °C (158 °F) for 20 minutes to eliminate the risk of infection. The Animal Health and Veterinary Laboratories Agency discovered hepatitis E in almost half of all pigs in Scotland.[58][59]

Hepatitis E infection appeared to be more common in people on hemodialysis, although the specific risk factors for transmission are not clear.[60]

Animal reservoir

edit

Hepatitis E due to genotypes other than 1 and 2 is thought to be a zoonosis, in that animals are thought to be the primary reservoir; deer and swine have frequently been implicated.[61] Domestic animals have been reported as a reservoir for the hepatitis E virus, with some surveys showing infection rates exceeding 95% among domestic pigs.[62] Replicative virus has been found in the small intestine, lymph nodes, colon, and liver of experimentally infected pigs. Transmission after consumption of wild boar meat and uncooked deer meat has been reported as well.[63] The rate of transmission to humans by this route and the public health importance of this are, however, still unclear.[64] Other animal reservoirs are possible but unknown at this time[17]

A number of other small mammals have been identified as potential reservoirs: the lesser bandicoot rat (Bandicota bengalensis), the black rat (Rattus rattus brunneusculus) and the Asian house shrew (Suncus murinus). A new virus designated rat hepatitis E virus has been isolated.[65]

Genomics

edit
Main article: Hepatitis E Virus

HEV has three open reading frames (ORFs) encoding two polyproteins (O1 and O2 protein). ORF2 encodes three capsid proteins whereas O1 encodes seven fragments involved in viral replication, among others.[66][67][68]

The smallest ORF of the HEV genome, ORF3 is translated from a subgenomic RNA into O3, a protein of 113–115 amino acids. ORF3 is proposed to play critical roles in immune evasion by HEV. Previous studies showed that ORF3 is bound to viral particles found in patient sera and produced in cell culture. Although in cultured cells ORF3 has not appeared essential for HEV RNA replication, viral assembly, or infection, it is required for particle release.[69]

 
Geldanamycin

Virus lifecycle

edit

The lifecycle of hepatitis E virus is unknown; the capsid protein obtains viral entry by binding to a cellular receptor. ORF2 (c-terminal) moderates viral entry by binding to HSC70.[70][71]

Geldanamycin blocks the transport of HEV239 capsid protein, but not the binding/entry of the truncated capsid protein, which indicates that Hsp90 plays an important part in HEV transport.[70]

Diagnosis

edit

In terms of the diagnosis of hepatitis E, only a laboratory blood test that confirms the presence of HEV RNA or IgM antibodies to HEV can be trusted.[11][72] In the United States no serologic tests for diagnosis of HEV infection have ever been authorized by the Food and Drug Administration.[11] The World Health Organization has developed an international standard strain for detection and quantification of HEV RNA.[73] In acute infection the viremic window for detection of HEV RNA closes 3 weeks after symptoms begin.[74]

Virological markers

edit

Assuming that vaccination has not occurred, tests may show:[5]

  • if the person's immune system is normal, then
    • if IgM anti-HEV is negative, then there is no evidence of recent HEV infection
    • if IgM anti-HEV is positive, then the person is likely to have a recent or current HEV infection
  • if the person's immune system is weakened by disease or medical treatment, as in the case of a person who has received a solid organ transplant, then
    • if IgM anti-HEV is negative, then if additional blood testing reveals
      • positive HEV RNA then the person has HEV infection
      • negative HEV RNA then there is no evidence of current or recent infection
    • if IgM anti-HEV is positive, then the person is likely to have a recent or current HEV infection, and HEV RNA may be useful to track resolution

Prevention

edit

Sanitation

edit

Sanitation is the most important measure in prevention of hepatitis E; this consists of proper treatment and disposal of human waste, higher standards for public water supplies, improved personal hygiene procedures, and sanitary food preparation. Thus, prevention strategies of this disease are similar to those of many other diseases that plague developing nations.[21] Cooking meat at 71 °C (159.8 °F) for five minutes kills the hepatitis E virus, different temperatures means different time to inactivate the virus.[59]

Blood products

edit

The amount of virus present in blood products required to cause transfusion-transmitted infection (TTI) appears variable. Transfusion transmission of hepatitis E virus can be screened via minipool HEV NAT (Nucleic acid testing) screening.[75][76] NAT is a technique used to screen blood molecularly, when blood donations are received; it screens for TTI.[77]

Vaccines

edit

A vaccine based on recombinant viral proteins was developed in the 1990s and tested in a high-risk population (in Nepal) in 2001.[78] The vaccine appeared to be effective and safe, but development was stopped for lack of profitability, since hepatitis E is rare in developed countries.[79] No hepatitis E vaccine is licensed for use in the United States.[11]

The exception is China; after more than a year of scrutiny and inspection by China's State Food and Drug Administration (SFDA), a hepatitis E vaccine developed by Chinese scientists was available at the end of 2012. The vaccine—called HEV 239 by its developer Xiamen Innovax Biotech—was approved for prevention of hepatitis E in 2012 by the Chinese Ministry of Science and Technology, following a controlled trial on 100,000+ people from Jiangsu Province where none of those vaccinated became infected during a 12-month period, compared to 15 in the group given placebo.[80] The first vaccine batches came out of Innovax's factory in late October 2012, to be sold to Chinese distributors.[79]

Due to lack of evidence, the World Health Organization has not made a recommendation regarding routine use of the HEV 239 vaccine as of 2015.[81] Its 2015 position was that national authorities may decide to use the vaccine based on their local epidemiology.[81]

Treatment

edit

There is no drug that has established safety and effectiveness for hepatitis E, and there have been no large randomized clinical trials of antiviral drugs.[8] Reviews of existing small studies suggest that ribavirin can be considered effective in immunocompromised people who have developed chronic infection.[82][83]

Chronic HEV infection is associated with immunosuppressive therapies, and when that happens in individuals with solid-organ transplantation, reducing immunosuppressive medications can result in clearance of HEV in one third of patients.[5]

Epidemiology

edit

The hepatitis E virus causes around 20 million infections a year. These result in around three million acute illnesses and resulted in 44,000 deaths during 2015.[8] Pregnant women are particularly at risk of complications due to HEV infection, who can develop an acute form of the disease that is fatal in 30% of cases or more. HEV is a major cause of illness and of death in the developing world and disproportionate cause of deaths among pregnant women. Hepatitis E is endemic in Central Asia, while Central America and the Middle East have reported outbreaks.[84][85] Increasingly, hepatitis E is being seen in developed nations, with reports in 2015 of 848 cases of hepatitis E virus infection in England and Wales.[86]

Recent outbreaks

edit

In October 2007, an epidemic of hepatitis E occurred in Kitgum District of northern Uganda. This outbreak progressed to become one of the largest known hepatitis E outbreaks in the world. By June 2009, it had resulted in illness in 10,196 persons and 160 deaths.[87] The aforementioned outbreak occurred despite no previous epidemics having been documented in the country, women were the most affected by HEV.[87]

 
Namibia, Africa

In July 2012, an outbreak was reported in South Sudanese refugee camps in Maban County near the Sudan border. South Sudan's Ministry of Health reported over 400 cases and 16 fatalities as of 13 September 2012.[88] Progressing further, as of 2 February 2013, 88 died due to the outbreak. The medical charity Medecins Sans Frontieres said it treated almost 4000 people.[89] In April 2014, an outbreak in the Biratnagar Municipality of Nepal resulted in infection of over 6000 locals and at least 9 dead.[90]

During an outbreak in Namibia, the number of affected people rose from 490 in January 2018, to 5014 (with 42 deaths) by April 2019, to 6151 cases (with 56 deaths) by August 2019; the WHO estimated that the case fatality rate was 0.9%.[91][92][93]

In Hong Kong in May 2020, there were at least 10 cases of hepatitis E that were transmitted by rats, and possibly hundreds of cases that had a transmission mechanism that is not fully understood.[94]

2024 outbreak in Finland. A record number of hepatitis E cases have been diagnosed in Finland so far this year, according to figures released on Tuesday by public health authority THL. Data from the authority's Infectious Diseases Register showed that a total of 92 lab-confirmed infections have been recorded since the beginning of January until 12 March, with 42 people requiring hospital treatment. The outbreak has been suspected to be caused by a batch of mettwurst that has been recalled. [95]

Evolution

edit

The strains of HEV that exist today may have arisen from a shared ancestor virus 536 to 1344 years ago.[96] Another analysis has dated the origin of Hepatitis E to ~6000 years ago, with a suggestion that this was associated with domestication of pigs.[97] At some point, two clades may have diverged — an anthropotropic form and an enzootic form — which subsequently evolved into genotypes 1 and 2 and genotypes 3 and 4, respectively.[98]

Whereas genotype 2 remains less commonly detected than other genotypes, genetic evolutionary analyses suggest that genotypes 1, 3, and 4 have spread substantially during the past 100 years.[17]

References

edit

This article incorporates public domain text from the CDC as cited

  1. ^ a b c d e "Hepatitis E | NIDDK". National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved 24 June 2018.
  2. ^ "Hepatitis A Differential Diagnoses". emedicine.medscape.com. Retrieved 27 July 2019.
  3. ^ a b James SL, et al. (10 November 2018). "Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017". Lancet. 392 (10159): 1789–1858. doi:10.1016/S0140-6736(18)32279-7. ISSN 0140-6736. PMC 6227754. PMID 30496104.
  4. ^ "Hepatitis E: Background, Etiopathophysiology, Epidemiology". medscape.com. Medscape. 2019.
  5. ^ a b c d e f g Kamar N, Dalton HR, Abravanel F, Izopet J (2014). "Hepatitis E Virus Infection". Clinical Microbiology Reviews. 27 (1): 116–138. doi:10.1128/CMR.00057-13. ISSN 0893-8512. PMC 3910910. PMID 24396139.
  6. ^ "Hepatitis (Viral) NIDDK". The National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved 2020-06-19.
  7. ^ "What is hepatitis?". www.who.int. WHO. Retrieved 17 April 2019.
  8. ^ a b c d e "Hepatitis E". www.who.int. WHO. Retrieved 17 April 2019.
  9. ^ Weston D, Burgess A, Roberts S (2016). Infection Prevention and Control at a Glance. John Wiley & Sons. p. 12. ISBN 978-1-118-97355-4.
  10. ^ a b Patra S, Kumar A, Trivedi SS, Puri M, Sarin SK (2007-07-03). "Maternal and Fetal Outcomes in Pregnant Women with Acute Hepatitis E Virus Infection". Annals of Internal Medicine. 147 (1): 28–33. doi:10.7326/0003-4819-147-1-200707030-00005. ISSN 0003-4819. PMID 17606958. S2CID 44504380.
  11. ^ a b c d "Hepatitis E Questions and Answers for Health Professionals". www.cdc.gov. CDC. 13 June 2018.
  12. ^ Zhou X, de Man RA, de Knegt RJ, Metselaar HJ, Peppelenbosch MP, Pan Q., De Man, De Knegt, Metselaar, Peppelenbosch, Pan (2013). "Epidemiology and management of chronic hepatitis E infection in solid organ transplantation: a comprehensive literature review". Rev. Med. Virol. 23 (5): 295–304. doi:10.1002/rmv.1751. PMID 23813631. S2CID 41424447.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  13. ^ Kamar N, Izopet J, Dalton HR (2013). "Chronic hepatitis e virus infection and treatment". Journal of Clinical and Experimental Hepatology. 3 (2): 134–140. doi:10.1016/j.jceh.2013.05.003. ISSN 0973-6883. PMC 3940092. PMID 25755487.
  14. ^ Kamar N, Abravanel F, Selves J, Garrouste C, Esposito L, Lavayssière L, Cointault O, Ribes D, Cardeau I, Nogier MB, Mansuy JM, Muscari F, Peron JM, Izopet J, Rostaing L (2010). "Influence of Immunosuppressive Therapy on the Natural History of Genotype 3 Hepatitis-E Virus Infection After Organ Transplantation". Transplantation. 89 (3): 353–360. doi:10.1097/tp.0b013e3181c4096c. PMID 20145528. S2CID 19917145.
  15. ^ Dalton HR, Kamar N, Baylis SA, Moradpour D, Wedemeyer H, Negro F (June 2018). "EASL Clinical Practice Guidelines on hepatitis E virus infection". Journal of Hepatology. 68 (6): 1256–1271. doi:10.1016/j.jhep.2018.03.005. PMID 29609832.
  16. ^ a b Sridhar S, Teng JL, Chiu TH, Lau SK, Woo PC (20 April 2017). "Hepatitis E Virus Genotypes and Evolution: Emergence of Camel Hepatitis E Variants". International Journal of Molecular Sciences. 18 (4): 869. doi:10.3390/ijms18040869. ISSN 1422-0067. PMC 5412450. PMID 28425927.
  17. ^ a b c d e f Izopet J, Abravanel F, Dalton HR, Kamar N (1 January 2014). "Hepatitis E Virus Infection". Clinical Microbiology Reviews. 27 (1): 116–138. doi:10.1128/CMR.00057-13. ISSN 0893-8512. PMC 3910910. PMID 24396139.
  18. ^ Li SW, Zhao Q, Wu T, Chen S, Zhang J, Xia NS (2015-02-25). "The development of a recombinant hepatitis E vaccine HEV 239". Human Vaccines & Immunotherapeutics. 11 (4): 908–914. doi:10.1080/21645515.2015.1008870. ISSN 2164-5515. PMC 4514148. PMID 25714510.
  19. ^ Kumar S, Subhadra S, Singh B, Panda B (April 2013). "Hepatitis E virus: the current scenario". International Journal of Infectious Diseases. 17 (4): e228–e233. doi:10.1016/j.ijid.2012.11.026. ISSN 1201-9712. PMID 23313154.
  20. ^ Sanford CA, Jong EC, Pottinger PS (2016). The Travel and Tropical Medicine Manual E-Book. Elsevier Health Sciences. p. 324. ISBN 978-0-323-41742-6.
  21. ^ a b c "Hepatitis E Fact sheet". WHO. Retrieved 17 April 2019.
  22. ^ a b Hoofnagle JH, Nelson KE, Purcell RH (2012). "Hepatitis E". New England Journal of Medicine. 367 (13): 1237–1244. doi:10.1056/NEJMra1204512. PMID 23013075. S2CID 32198953.
  23. ^ "Facts about hepatitis E". ecdc.europa.eu. European Centre for Disease Prevention and Control. 30 March 2017. Retrieved 17 April 2019.
  24. ^ Bonnet D, Kamar N, Izopet J, Alric L (2012). "L'hépatite virale E : Une maladie émergente". La Revue de Médecine Interne. 33 (6): 328–334. doi:10.1016/j.revmed.2012.01.017. PMID 22405325.
  25. ^ Behrendt P, Steinmann E, Manns MP, Wedemeyer H (2014-12-01). "The impact of hepatitis E in the liver transplant setting". Journal of Hepatology. 61 (6): 1418–1429. doi:10.1016/j.jhep.2014.08.047. hdl:10033/346563. PMID 25195557.
  26. ^ Kamar N, Pischke S (7 May 2018). "Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment". Cold Spring Harbor Perspectives in Medicine. 9 (7): a031872. doi:10.1101/cshperspect.a031872. ISSN 2157-1422. PMC 6601456. PMID 29735575.
  27. ^ Bazerbachi F, Haffar S, Garg SK, Lake JR (February 2016). "Extra-hepatic manifestations associated with hepatitis E virus infection: a comprehensive review of the literature". Gastroenterology Report. 4 (1): 1–15. doi:10.1093/gastro/gov042. PMC 4760069. PMID 26358655.
  28. ^ Rivero-Juárez A, Aguilera A, Avellón A, García-Deltoro M, García F, Gortazar C, Granados R, Macías J, Merchante N, Oteo JA, Pérez-Gracia MT, Pineda JA, Rivero A, Rodriguez-Lazaro D, Téllez F, Morano-Amado LE (30 July 2018). "Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)". Enfermedades Infecciosas y Microbiologia Clinica. 38 (1): 28–32. doi:10.1016/j.eimc.2018.06.014. hdl:10498/23059. ISSN 1578-1852. PMID 30072282.
  29. ^ Kamar N, Bendall RP, Peron JM, Cintas P, Prudhomme L, Mansuy JM, Rostaing L, Keane F, Ijaz S, Izopet J, Dalton HR (2011). "Hepatitis E virus and neurologic disorders". Emerging Infectious Diseases. 17 (2): 173–179. doi:10.3201/eid1702.100856. ISSN 1080-6059. PMC 3298379. PMID 21291585.
  30. ^ Dalton HR, Kamar N, van Eijk JJ, Mclean BN, Cintas P, Bendall RP, Jacobs BC (29 December 2015). "Hepatitis E virus and neurological injury". Nature Reviews Neurology. 12 (2): 77–85. doi:10.1038/nrneurol.2015.234. ISSN 1759-4766. PMID 26711839. S2CID 25495184.
  31. ^ Kumar A., Beniwal M., Kar P., Sharma J.B., Murthy N.S. (2004). "Wiley Online Library". International Journal of Gynecology & Obstetrics. 85 (3): 240–244. doi:10.1016/j.ijgo.2003.11.018. PMID 15145258. S2CID 72665101.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  32. ^ Khuroo MS, Khuroo MS, Khuroo NS (20 September 2016). "Transmission of Hepatitis E Virus in Developing Countries". Viruses. 8 (9): 253. doi:10.3390/v8090253. ISSN 1999-4915. PMC 5035967. PMID 27657112.
  33. ^ a b Pérez-Gracia MT, Suay-García B, Mateos-Lindemann ML (20 March 2017). "Hepatitis E and pregnancy: current state". Reviews in Medical Virology. 27 (3): e1929. doi:10.1002/rmv.1929. ISSN 1099-1654. PMID 28318080. S2CID 44761962.
  34. ^ Bose PD, Das BC, Hazam RK, Kumar A, Medhi S, Kar P (2014). "Evidence of extrahepatic replication of hepatitis E virus in human placenta". Journal of General Virology. 95 (6): 1266–1271. doi:10.1099/vir.0.063602-0. PMID 24622580.
  35. ^ Feldman M, Friedman LS, Brandt LJ (2010). Sleisenger and Fordtran's Gastrointestinal and Liver Disease E-Book: Pathophysiology, Diagnosis, Management, Expert Consult Premium Edition - Enhanced Online Features. Elsevier Health Sciences. p. 1337. ISBN 978-1-4377-2767-8. Retrieved 27 June 2020.
  36. ^ Wang Y (2016). Hepatitis E Virus. Springer. p. 75. ISBN 978-94-024-0942-0.
  37. ^ Wang Y (2016). Hepatitis E Virus. Springer. p. 10. ISBN 978-94-024-0942-0.
  38. ^ a b Boyer TD, Manns MP, Sanyal AJ, Zakim D (2012). Zakim and Boyer's Hepatology: A Textbook of Liver Disease. Elsevier Health Sciences. p. 609. ISBN 978-1-4377-0881-3.
  39. ^ Johne R, Heckel G, Plenge-Bönig A, Kindler E, Maresch C, Reetz J, Schielke A, Ulrich RG (2010). "Novel hepatitis E virus genotype in Norway rats, Germany". Emerging Infectious Diseases. 16 (9): 1452–1455. doi:10.3201/eid1609.100444. ISSN 1080-6059. PMC 3294985. PMID 20735931.
  40. ^ Sridhar S, Yip CC, Wu S, Cai J, Zhang AJ, Leung KH, Chung TW, Chan JF, Chan WM, Teng JL, Au-Yeung RK, Cheng VC, Chen H, Lau SK, Woo PC, Xia NS, Lo CM, Yuen KY (December 2018). "Rat Hepatitis E Virus as Cause of Persistent Hepatitis after Liver Transplant". Emerging Infectious Diseases. 24 (12): 2241–2250. doi:10.3201/eid2412.180937. PMC 6256372. PMID 30457530.
  41. ^ a b c Song YJ (2010-11-01). "Studies of hepatitis E virus genotypes". The Indian Journal of Medical Research. 132 (5): 487–488. ISSN 0971-5916. PMC 3028963. PMID 21149996.
  42. ^ Pelosi E, Clarke I (2008-11-07). "Hepatitis E: a complex and global disease". Emerging Health Threats Journal. 1: e8. doi:10.3134/ehtj.08.008 (inactive 2024-03-31). ISSN 1752-8550. PMC 3167588. PMID 22460217.{{cite journal}}: CS1 maint: DOI inactive as of March 2024 (link)
  43. ^ Hepatitis E Vaccine Working Group (1 October 2014). Recommendations of HEV Working Group on the use of hepatitis E vaccine (PDF). www.who.int (Report). WHO.
  44. ^ Guerrant RL, Walker DH, Weller PF (2011). Tropical Infectious Diseases: Principles, Pathogens and Practice (Expert Consult – Online and Print). Elsevier Health Sciences. p. 424. ISBN 978-1-4377-3777-6.
  45. ^ Meng XJ (2010-01-27). "Hepatitis E virus: Animal Reservoirs and Zoonotic Risk". Veterinary Microbiology. 140 (3–4): 256–65. doi:10.1016/j.vetmic.2009.03.017. ISSN 0378-1135. PMC 2814965. PMID 19361937.
  46. ^ Woolson KL, Forbes A, Vine L, Beynon L, McElhinney L, Panayi V, Hunter JG, Madden RG, Glasgow T, Kotecha A, Dalton HC, Mihailescu L, Warshow U, Hussaini HS, Palmer J, Mclean BN, Haywood B, Bendall RP, Dalton HR (2014). "Extra-hepatic manifestations of autochthonous hepatitis E infection". Alimentary Pharmacology & Therapeutics. 40 (11–12): 1282–1291. doi:10.1111/apt.12986. ISSN 1365-2036. PMID 25303615. S2CID 207050371.
  47. ^ Berto A, Grierson S, Hakze-van der Honing R, Martelli F, Johne R, Reetz J, Ulrich RG, Pavio N, Van der Poel WH, Banks M (February 2013). "Hepatitis E virus in pork liver sausage, France". Emerging Infectious Diseases. 19 (2): 264–6. doi:10.3201/eid1902.121255. PMC 3563277. PMID 23347828.
  48. ^ Liu D (2010-11-23). Molecular Detection of Human Viral Pathogens. CRC Press. p. 102. ISBN 978-1-4398-1237-2.
  49. ^ Dai X, Dong C, Zhou Z, Liang J, Dong M, Yang Y, Fu J, Tian H, Wang S, Fan J, Meng J, Purdy MA (2013). "Hepatitis E Virus Genotype 4, Nanjing, China, 2001–2011". Emerging Infectious Diseases. 19 (9): 1528–1530. doi:10.3201/eid1909.130013. ISSN 1080-6040. PMC 3810912. PMID 23965731.
  50. ^ Kanki P, Grimes DJ (2012). Infectious Diseases: Selected Entries from the Encyclopedia of Sustainability Science and Technology. Springer Science & Business Media. p. 391. ISBN 978-1-4614-5719-0.
  51. ^ Griffiths J, Maguire JH, Heggenhougen K, Quah SR (2010-03-09). Public Health and Infectious Diseases. Elsevier. ISBN 978-0-12-381507-1.
  52. ^ Guerin PJ, Nicand E, Ciglenecki I, Grais RF, Moren A, Diaz F, Tatay M, Nizou JY, Pinoges L, Hamid N, Boccia D, Klovstad H, Guthmann JP (15 June 2006). "A Large Outbreak of Hepatitis E among a Displaced Population in Darfur, Sudan, 2004: The Role of Water Treatment Methods". Clinical Infectious Diseases. 42 (12): 1685–1691. doi:10.1086/504321. ISSN 1058-4838. PMID 16705572.
  53. ^ a b Bitton G (2005-05-27). Wastewater Microbiology. John Wiley & Sons. p. 132. ISBN 978-0-471-71791-1.
  54. ^ Hubálek Z, Rudolf I (2010-11-25). Microbial Zoonoses and Sapronoses. Springer Science & Business Media. p. 189. ISBN 978-90-481-9657-9.
  55. ^ Khuroo MS (2011-10-01). "Discovery of hepatitis E: The epidemic non-A, non-B hepatitis 30 years down the memory lane". Virus Research. Hepatitis E Viruses. 161 (1): 3–14. doi:10.1016/j.virusres.2011.02.007. PMID 21320558.
  56. ^ Cowie BC, Adamopoulos J, Carter K, Kelly H (2005-03-01). "Hepatitis E Infections, Victoria, Australia". Emerging Infectious Diseases. 11 (3): 482–484. doi:10.3201/eid1103.040706. ISSN 1080-6040. PMC 3298235. PMID 15757573.
  57. ^ Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST (2012). "The global burden of hepatitis E virus genotypes 1 and 2 in 2005". Hepatology. 55 (4): 988–997. doi:10.1002/hep.25505. ISSN 1527-3350. PMID 22121109. S2CID 25571762.
  58. ^ Doward, Jamie (21 September 2013). "Chefs fight for the right to serve their pork pink". The Observer newspaper.
  59. ^ a b "Hepatitis E Virus and Food". www.fsai.ie. Food Safety Authority of Ireland. 11 July 2017. Archived from the original on 28 May 2019. Retrieved 27 July 2019.
  60. ^ Haffar S, Bazerbachi F (2017-09-04). "Systematic review with meta-analysis: the association between hepatitis E seroprevalence and haemodialysis". Aliment Pharmacol Ther. 46 (9): 790–799. doi:10.1111/apt.14285. PMID 28869287. S2CID 24480333.
  61. ^ Pavio N, Meng XJ, Renou C (2010-01-01). "Zoonotic hepatitis E: animal reservoirs and emerging risks". Veterinary Research. 41 (6): 46. doi:10.1051/vetres/2010018. ISSN 0928-4249. PMC 2865210. PMID 20359452.
  62. ^ Satou K, Nishiura H, Nishiura (2007). "Transmission Dynamics of Hepatitis E Among Swine: Potential Impact upon Human Infection". BMC Vet. Res. 3: 9. doi:10.1186/1746-6148-3-9. PMC 1885244. PMID 17493260.
  63. ^ Li TC, Chijiwa K, Sera N (2005). "Hepatitis E Virus Transmission from Wild Boar Meat". Emerging Infect. Dis. 11 (12): 1958–60. doi:10.3201/eid1112.051041. PMC 3367655. PMID 16485490.
  64. ^ Kuniholm MH & Nelson KE (2008). "Of Organ Meats and Hepatitis E Virus: One Part of a Larger Puzzle Is Solved". J Infect Dis. 198 (12): 1727–1728. doi:10.1086/593212. PMID 18983247.
  65. ^ Johne R, Plenge-Bönig A, Hess M, Ulrich RG, Reetz J, Schielke A, Plenge-Bönig, Hess, Ulrich, Reetz, Schielke (2010). "Detection of a novel hepatitis E-like virus in faeces of wild rats using a nested broad-spectrum RT-PCR". J. Gen. Virol. 91 (Pt 3): 750–758. doi:10.1099/vir.0.016584-0. PMID 19889929.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  66. ^ Balakrishnan V, Rajesh G (2016). Practical Gastroenterology. JP Medical Ltd. p. 195. ISBN 978-93-5250-190-8. Retrieved 22 July 2019.
  67. ^ Cocquerel L, Dubuisson J, Meuleman P, d'Autume Vd, Farhat R, Aliouat-Denis CM, Duvet S, Saas L, Wychowski C, Saliou JM, Sayed IM, Montpellier C, Ankavay M (18 April 2019). "New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle". Scientific Reports. 9 (1): 6243. Bibcode:2019NatSR...9.6243A. doi:10.1038/s41598-019-42737-2. ISSN 2045-2322. PMC 6472401. PMID 31000788.
  68. ^ Ahmad I, Holla RP, Jameel S (October 2011). "Molecular Virology of Hepatitis E Virus". Virus Research. 161 (1): 47–58. doi:10.1016/j.virusres.2011.02.011. ISSN 0168-1702. PMC 3130092. PMID 21345356.
  69. ^ Ding Q, Heller B, Capuccino JM, Song B, Nimgaonkar I, Hrebikova G, Contreras JE, Ploss A (2017). "Hepatitis E virus ORF3 is a functional ion channel required for release of infectious particles". Proceedings of the National Academy of Sciences of the United States of America. 114 (5): 1147–1152. Bibcode:2017PNAS..114.1147D. doi:10.1073/pnas.1614955114. ISSN 1091-6490. PMC 5293053. PMID 28096411.
  70. ^ a b Cao D, Meng XJ (2012-08-22). "Molecular biology and replication of hepatitis E virus". Emerging Microbes & Infections. 1 (8): e17. doi:10.1038/emi.2012.7. PMC 3630916. PMID 26038426.
  71. ^ Tao TS, Liu, Z, Ye, Q, Mata, DA, Li, K, Yin, C, Zhang, J, Tao, YJ (Aug 4, 2009). "Structure of the hepatitis E virus-like particle suggests mechanisms for virus assembly and receptor binding". Proceedings of the National Academy of Sciences of the United States of America. 106 (31): 12992–7. Bibcode:2009PNAS..10612992G. doi:10.1073/pnas.0904848106. PMC 2722310. PMID 19622744.
  72. ^ Aggarwal R (2 October 2012). "Diagnosis of hepatitis E". Nature Reviews Gastroenterology & Hepatology. 10 (1): 24–33. doi:10.1038/nrgastro.2012.187. ISSN 1759-5045. PMID 23026902. S2CID 11958858.subscription needed
  73. ^ Baylis SA, Blümel J, Mizusawa S, Matsubayashi K, Sakata H, Okada Y, Nübling CM, Hanschmann KM (May 2013). "World Health Organization International Standard to Harmonize Assays for Detection of Hepatitis E Virus RNA". Emerging Infectious Diseases. 19 (5): 729–735. doi:10.3201/eid1905.121845. ISSN 1080-6040. PMC 3647515. PMID 23647659.
  74. ^ Webb GW, Dalton HR (3 April 2019). "Hepatitis E: an underestimated emerging threat". Therapeutic Advances in Infectious Disease. 6: 204993611983716. doi:10.1177/2049936119837162. ISSN 2049-9361. PMC 6448100. PMID 30984394.
  75. ^ Hillyer CD, Shaz BH, Zimring JC, Abshire TC (2009). Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. Elsevier. p. 364. ISBN 978-0-08-092230-0.
  76. ^ Dreier J, Knabbe C, Vollmer T (1 February 2018). "Transfusion-Transmitted Hepatitis E: NAT Screening of Blood Donations and Infectious Dose". Frontiers in Medicine. 5: 5. doi:10.3389/fmed.2018.00005. ISSN 2296-858X. PMC 5799287. PMID 29450199.
  77. ^ Hans R, Marwaha N (2014). "Nucleic acid testing-benefits and constraints". Asian Journal of Transfusion Science. 8 (1): 2–3. doi:10.4103/0973-6247.126679. ISSN 0973-6247. PMC 3943139. PMID 24678164.
  78. ^ Shrestha MP, Scott RM, Joshi DM (2007). "Safety and efficacy of a recombinant hepatitis E vaccine". New England Journal of Medicine. 356 (9): 895–903. doi:10.1056/NEJMoa061847. PMID 17329696.
  79. ^ a b Park SB (November 2012). "Hepatitis E vaccine debuts". Nature. 491 (7422): 21–22. Bibcode:2012Natur.491...21P. doi:10.1038/491021a. PMID 23128204.
  80. ^ Labrique AB, Sikder SS, Krain LJ, West KP, Christian P, Rashid M, Nelson KE (2012-09-01). "Hepatitis E, a Vaccine-Preventable Cause of Maternal Deaths". Emerging Infectious Diseases. 18 (9): 1401–1404. doi:10.3201/eid1809.120241. ISSN 1080-6040. PMC 3437697. PMID 22931753.
  81. ^ a b "Hepatitis E vaccine: WHO position paper, May 2015" (PDF). Relevé Épidémiologique Hebdomadaire. 90 (18): 185–200. 1 May 2015. PMID 25935931.
  82. ^ Dalton HR, Kamar N (2016). "Treatment of hepatitis E virus". Current Opinion in Infectious Diseases. 29 (6): 639–644. doi:10.1097/QCO.0000000000000316. ISSN 1473-6527. PMID 27607911. S2CID 25304902.
  83. ^ Peters van Ton AM, Gevers TJ, Drenth JP (Dec 2015). "Antiviral therapy in chronic hepatitis E: a systematic review". Journal of Viral Hepatitis. 22 (12): 965–973. doi:10.1111/jvh.12403. ISSN 1365-2893. PMID 25760481. S2CID 10199788.
  84. ^ Teshale EH (31 May 2017). "Hepatitis E – Infectious Diseases Related to Travel Chapter 3 – 2018 Yellow Book". www.cdc.gov. CDC.
  85. ^ Navaneethan U, Mohajer MA, Shata MT (2008). "Hepatitis E and Pregnancy- Understanding the pathogenesis". Liver International. 28 (9): 1190–1199. doi:10.1111/j.1478-3231.2008.01840.x. ISSN 1478-3223. PMC 2575020. PMID 18662274.
  86. ^ Public Health England ir. "Common animal associated infections quarterly report (England and Wales) – fourth quarter 2015" (PDF). gov.uk. Retrieved 27 July 2019.
  87. ^ a b Teshale EH, Howard CM, Grytdal SP (2010). "Hepatitis E epidemic, Uganda". Emerging Infect. Dis. 16 (1): 126–129. doi:10.3201/eid1601.090764. PMC 2874362. PMID 20031058.
  88. ^ Investigation of Hepatitis E Outbreak Among Refugees — Upper Nile, South Sudan, 2012–2013. www.cdc.gov (Report). Vol. 62. CDC Morbidity and Mortality Weekly Report. 26 July 2013. pp. 581–586.
  89. ^ Hereward Holland (2 February 2013). "Hepatitis outbreak kills 88 in South Sudan—aid agency". Reuters. Archived from the original on March 5, 2016.
  90. ^ Sharma C (5 September 2014). "Nepal, hepatitis E epidemic: 9 dead and over 6 thousand infected". www.asianews.it.
  91. ^ "Hepatitis E cases in Namibia rise to 490". www.xinhuanet.com. Xinhua News. 28 January 2018. Archived from the original on January 29, 2018.
  92. ^ "Weekly bulletins on outbreaks and other emergencies" (PDF). World Health Organization. WHO.int. Retrieved 20 May 2019.
  93. ^ "Outbreaks and Emergencies Bulletin, Week 33: 12 – 18 August 2019". WHO | Regional Office for Africa. Retrieved 20 August 2019.
  94. ^ Jessie Yeung (8 May 2020). "Rats are infecting humans with hepatitis, and nobody knows how". CNN. Retrieved 11 May 2020.
  95. ^ "THL: Finland faces hepatitis E epidemic with record number of cases". YLE. 12 March 2024. Retrieved 13 March 2024.
  96. ^ Khudyakov YE, Purdy MA (2010). "Evolutionary History and Population Dynamics of Hepatitis E Virus". PLOS ONE. 5 (12): e14376. Bibcode:2010PLoSO...514376P. doi:10.1371/journal.pone.0014376. ISSN 1932-6203. PMC 3006657. PMID 21203540.
  97. ^ Baha S, Behloul N, Liu Z, Wei W, Shi R, Meng J (2019-10-29). "Comprehensive analysis of genetic and evolutionary features of the hepatitis E virus". BMC Genomics. 20 (1): 790. doi:10.1186/s12864-019-6100-8. ISSN 1471-2164. PMC 6820953. PMID 31664890.
  98. ^ Mirazo S, Mir D, Bello G, Ramos N, Musto H, Arbiza J (2016). "New insights into the hepatitis E virus genotype 3 phylodynamics and evolutionary history". Infect Genet Evol. 43: 267–273. Bibcode:2016InfGE..43..267M. doi:10.1016/j.meegid.2016.06.003. PMID 27264728.{{cite journal}}: CS1 maint: multiple names: authors list (link)

  This article was submitted to WikiJournal of Medicine for external academic peer review in 2018 (reviewer reports). The updated content was reintegrated into the Wikipedia page under a CC-BY-SA-3.0 license (2019). The version of record as reviewed is: Osmin Anis, et al. (27 July 2019). "Hepatitis E". WikiJournal of Medicine. 6 (1): 3. doi:10.15347/WJM/2019.003. ISSN 2002-4436. Wikidata Q73053451.

Further reading

edit
edit
 
Scholia has a topic profile for Hepatitis E.
 
Wikimedia Commons has media related to Hepatitis E.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Hepatitis_E&oldid=1246922392#Vaccines"